Although BCG produces an anti-tumor environment affecting the innate immune system, it has been reported that BCG instillations in NMIBC patients also induce immune anti-tumor responses mediated by CD4+ T cells and CD8+ cytotoxic T lymphocytes. The gene discussed is CD8A; the disease is neoplasm.